Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance

Neoplasma

Volumn 58, Issue 5, 2011, Pages 449-454

  Zeng, H Z ^a   Qu, Y Q ^b   Liang, A B ^c   Deng, A M ^d   Zhang, W J ^c   Xiu, B ^c   Wang, H ^a  

^a TONGJI UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD147; Non small cell lung cancer; Resistance

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CD147 ANTIGEN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; BSG PROTEIN, HUMAN; DEOXYCYTIDINE; DRUG DERIVATIVE; VINBLASTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CELL PROLIFERATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG INHIBITION; FEMALE; GENE EXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PROGNOSIS; REPEATED DRUG DOSE; RNA INTERFERENCE; TREATMENT RESPONSE; ADENOCARCINOMA; CELL MEMBRANE; DRUG EFFECT; DRUG RESISTANCE; ENZYME IMMUNOASSAY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIGENS, CD147; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 80052886597     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_05_449     Document Type: Article

References (24)

1. WU YL, ZHONG WZ, LI LY, ZHANG XT, ZHANG L et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with nonsmall cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007; 2: 430-439. doi:10.1097/01. JTO.0000268677.87496.4c
2. MARTINS RG. Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation. Semin Respir Crit Care Med 2005; 26: 273-237. doi:10.1055/s-2005-871985
3. REN JH, HE WS, NONG L, ZHU QY, HU K et al. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 2010; 25: 75-80. doi:10.1089/cbr.2009.0701
4. WANG G, REED E, LI QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004; 12: 955-965.
5. BISWAS C, ZHANG Y, DECASTRO R, GUO H, NAKAMURA T, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-439.
6. NABESHIMA K, IWASAKI H, KOGA K, HOJO H, Suzumi-Ya J et al. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006; 56: 359-367. doi:10.1111/j.1440-1827.2006.01972.x
7. TOOLE BP, SLOMIANY MG. HYALURONAN. CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 2008; 11: 110-121. doi:10.1016/j.drup.2008.04.002
8. DEAN NR, NEWMAN JR, HELMAN EE, ZHANG W, Sa-Favy S et al. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 15 2009; 12: 4058-4065.
9. ZHANG Z, BIAN H, FENG Q, MI L, MO T et al. Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther 2006; 5: 318-322. doi:10.4161/cbt.5.3.2431
10. ZHU H, YANG B, YANG X, WANG L, XU J et al. A novel antibody fragment targeting HAb18G/CD147 with cytotoxicity and decreased immunogenicity. Cancer Biol Ther 2009, 8: 1035-1044. doi:10.4161/cbt.8.11.8531
11. CHEN ZN, MI L, XU J, SONG F, ZHANG Q et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006; 65: 435-444. doi:10.1016/j.ijrobp.2005.12.034
12. HAN ZD, HE HC, BI XC, QIN WJ, DAI QS et al. Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res 2010; 160: 260-267. doi:10.1016/j.jss.2008.11.838
13. LEI X, HUANG Z, ZHONG M, ZHU B, TANG S et al. Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells. Acta Biochim Biophys Sin (Shanghai) 2007; 39: 344-350. doi:10.1111/j.1745-7270.2007.00286.x
14. RIETHDORF S, REIMERS N, ASSMANN V, KORNFELD JW, TERRACCIANO L et al. High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006; 119: 1800-1810. doi:10.1002/ijc.22062
15. SIENEL W, POLZER B, ELSHAWI K, LINDNER M, Mor-Resi-Hauf A et al. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod Pathol 2008; 21: 1130-1138. doi:10.1038/modpathol.2008.102
16. SIDHU SS, NAWROTH R, RETZ M, Lemjabbar-Alaoui H, DASARI V et al. EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene 2010; 29: 4145-4156. doi:10.1038/onc.2010.166
17. KONG LM, LIAO CG, FEI F, GUO X, XING JL et al. Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer. Cancer Sci 2010; 101: 1463-1470. doi:10.1111/j.1349-7006.2010.01554.x
18. JIA L, WEI W, CAO J, XU H, MIAO X et al. Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells. Ann Hematol 2009; 88: 753-760. doi:10.1007/s00277-008-0678-2
19. KUANG YH, CHEN X, SU J, WU LS, LIAO LQ et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett 2009; 276: 189-195. doi:10.1016/j.canlet.2008.11.010
20. YANG H, ZOU W, LI Y, CHEN B, XIN X. Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells. Cancer Biol Ther 2007; 6: 942-947. doi:10.4161/cbt.6.6.4190
21. SLOMIANY MG, DAI L, TOLLIVER LB, GRASS GD, ZENG Y et al. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 2009; 15:7593-7601. doi:10.1158/1078-0432.CCR-09-2317
22. GALLAGHER SM, CASTORINO JJ, WANG D, PHILP NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007: 67: 4182-4189. doi:10.1158/0008-5472.CAN-06-3184
23. SLOMIANY MG, GRASS GD, ROBERTSON AD, YANG XY, MARIA BL et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarb-oxylate transporters in human breast carcinoma cells. Cancer Res 2009; 69: 1293-1301. doi:10.1158/0008-5472.CAN-08-2491
24. KENNEDY KM, DEWHIRST MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010; 6: 127-148. doi:10.2217/fon.09.145